CARDIFF ONCOLOGY INC (CRDF) Stock News
NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock - Currency: USD
CRDF Latest News, Press Relases and Analysis
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ADCT
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of...
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to...
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial...
What's Going On With Cardiff Oncology Stock On Tuesday?
Cardiff Oncology's CRDF-004 trial shows promising onvansertib results in RAS-mutated mCRC patients, with higher tumor response rates and a strong safety profile.
CRDF Stock Earnings: Cardiff Oncology Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cardiff Oncology (NASDAQ:CRDF) just reported results for the second quarter of ...
CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cardiff Oncology (NASDAQ:CRDF) just reported results for the first quarter of 2...
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004)...
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. ...
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
What's Going On With Cardiff Oncology Stock On Tuesday?
On Tuesday, Cardiff Oncology, Inc. (NASDAQ:CRDF) revealed initial data from the CRDF-004 Phase 2 trial, which evaluates onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation. Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology...
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg...
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line...
CRDF Stock Earnings: Cardiff Oncology Misses EPS, Beats Revenue for Q2 2024
CRDF stock results show that Cardiff Oncology missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Cardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to...
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Finding good investing possibilities in the constantly changing stock market might be likened to unearthing buried jewels.
CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024
CRDF stock results show that Cardiff Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) --...
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in...